NCT00699153

Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery

Safety and Efficacy of Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 400 (actual)
• Sponsor: Bausch & Lomb Incorporated · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Evaluation of the clinical safety and efficacy of loteprednol etabonate in an ophthalmic base, when compared to vehicle for the treatment of inflammation following cataract surgery.

Conditions

• Ocular Inflammation

Interventions

Type	Name	Description
DRUG	Loteprednol Etabonate	Loteprednol Etabonate in an ophthalmic base will be administered to study eye 4 times a day(QID) for 14 days.
DRUG	Vehicle of Ophthalmic Loteprednol Etabonate	Vehicle of ophthalmic loteprednol etabonate administered postoperatively to study eye 4 times a day(QID) for 14 days.

Timeline

• Start date: 2008-06-01
• Primary completion: 2009-05-01
• Completion: 2009-06-01
• First posted: 2008-06-17
• Last updated: 2015-03-24
• Results posted: 2010-09-23

Locations

1 site across 1 country: United States